MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Sweden
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 152
- Registration Number
- NCT01307059
- Locations
- 🇸🇪
Merck Serono Research Site, Uppsala, Sweden
A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Terminated
- Conditions
- Unresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckLA SCCHN
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 88
- Registration Number
- NCT01303237
- Locations
- 🇮🇳
Cancer Care Centre, Jaipur, Rajasthan, India
🇮🇳Balaji Clinic & General Hospital, Jaipur, Rajasthan, India
🇮🇳Shanti Chandra Family Clinic, Hyderabad, Andhra Pradesh, India
PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
Phase 3
Completed
- Conditions
- Assisted Reproductive TechniquesReproductive Technology, Assisted
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 202
- Registration Number
- NCT01297465
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Austria
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 50
- Registration Number
- NCT01296425
- Locations
- 🇦🇹
For Recruiting, Locations In, Austria
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 223
- Registration Number
- NCT01291394
- Locations
- 🇫🇷
Contact Merck KGaA, Communication Center, France
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Phase 2
Completed
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo plus interferon beta-1a (Rebif)Biological: Interferon beta-1a (Rebif®) aloneDrug: VigantOL oil plus interferon beta-1a (Rebif)
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 260
- Registration Number
- NCT01285401
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 205
- Registration Number
- NCT01267526
- Locations
- 🇨🇦
Merck Serono Research Site, Sherbrooke, Quebec, Canada
Neuropathic Pain Management
Phase 3
Completed
- Conditions
- Diabetic NeuropathiesPolyneuropathies
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 104
- Registration Number
- NCT01263132
- Locations
- 🇲🇽
REMEDI Resultados Médicos Desarrollo e Investigación, S.C., Pachuca, Hidalgo, Mexico
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 191
- Registration Number
- NCT01263457
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 224
- Registration Number
- NCT01259778
- Locations
- 🇰🇷
Yonsei University Colleage of Medicine, Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath